These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

664 related items for PubMed ID: 18612155

  • 1. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS.
    J Clin Oncol; 2008 Jul 10; 26(20):3403-10. PubMed ID: 18612155
    [Abstract] [Full Text] [Related]

  • 2. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P.
    N Engl J Med; 2011 Feb 10; 364(6):501-13. PubMed ID: 21306237
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.
    Ito T, Tori M, Hashigaki S, Kimura N, Sato K, Ohki E, Sawaki A, Okusaka T.
    Jpn J Clin Oncol; 2019 Apr 01; 49(4):354-360. PubMed ID: 30834940
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
    Mizuno Y, Kudo A, Akashi T, Akahoshi K, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tanaka S, Tateishi U, Tanabe M.
    J Cancer Res Clin Oncol; 2018 Jun 01; 144(6):1155-1163. PubMed ID: 29602973
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD.
    J Clin Oncol; 2008 Apr 10; 26(11):1810-6. PubMed ID: 18347007
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
    Papaetis GS, Syrigos KN.
    BioDrugs; 2009 Apr 10; 23(6):377-89. PubMed ID: 19894779
    [Abstract] [Full Text] [Related]

  • 15. Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors.
    Deeks ED, Raymond E.
    BioDrugs; 2011 Oct 01; 25(5):307-16. PubMed ID: 21942915
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
    Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C, Kondo S, Mizuno N, Hara K, Sawaki A, Hashigaki S, Kimura N, Murakami M, Ohki E, Chao RC, Imamura M.
    Invest New Drugs; 2013 Oct 01; 31(5):1265-74. PubMed ID: 23269537
    [Abstract] [Full Text] [Related]

  • 18. Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor.
    Lin LZ, Li P, Chen HR, Pang LJ.
    Future Oncol; 2013 Jun 01; 9(6):909-13. PubMed ID: 23718311
    [Abstract] [Full Text] [Related]

  • 19. Assessment of the safety and efficiency of sunitinib malate in metastatic neuroendocrine tumours of the pancreas (NEN G1/G2) depending on the number and type of earlier therapeutic lines - initial report.
    Wachuła E, Ćwikła JB, Rogowski W, Boratyn-Nowicka A, Szabłowska-Siwik S, Piątek M, Zemczak A, Michalik B, Jarząb B, Nawrocki S, Kos-Kudła B.
    Endokrynol Pol; 2014 Jun 01; 65(6):472-8. PubMed ID: 25554616
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
    Raymond E, Kulke MH, Qin S, Yu X, Schenker M, Cubillo A, Lou W, Tomasek J, Thiis-Evensen E, Xu JM, Croitoru AE, Khasraw M, Sedlackova E, Borbath I, Ruff P, Oberstein PE, Ito T, Jia L, Hammel P, Shen L, Shrikhande SV, Shen Y, Sufliarsky J, Khan GN, Morizane C, Galdy S, Khosravan R, Fernandez KC, Rosbrook B, Fazio N.
    Neuroendocrinology; 2018 Jun 01; 107(3):237-245. PubMed ID: 29991024
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.